Subscribe
shutterstock_1197730855_photobyphm
photobyphm / Shutterstock.com
29 July 2019Big PharmaRory O'Neill

Pfizer off-patent division to merge with Mylan

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB